Ravi Vij

27.9k total citations
469 papers, 9.6k citations indexed

About

Ravi Vij is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ravi Vij has authored 469 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 410 papers in Hematology, 205 papers in Molecular Biology and 167 papers in Oncology. Recurrent topics in Ravi Vij's work include Multiple Myeloma Research and Treatments (321 papers), Protein Degradation and Inhibitors (128 papers) and Hematopoietic Stem Cell Transplantation (80 papers). Ravi Vij is often cited by papers focused on Multiple Myeloma Research and Treatments (321 papers), Protein Degradation and Inhibitors (128 papers) and Hematopoietic Stem Cell Transplantation (80 papers). Ravi Vij collaborates with scholars based in United States, Canada and France. Ravi Vij's co-authors include John F. DiPersio, Peter Westervelt, Keith Stockerl‐Goldstein, Sundar Jagannath, Geoffrey L. Uy, Mark A. Fiala, David S. Siegel, Michael P. Rettig, Camille N. Abboud and Sagar Lonial and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ravi Vij

446 papers receiving 9.4k citations

Peers

Countries citing papers authored by Ravi Vij

Since Specialization

Citations

This map shows the geographic impact of Ravi Vij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravi Vij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravi Vij more than expected).

Fields of papers citing papers by Ravi Vij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravi Vij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravi Vij. The network helps show where Ravi Vij may publish in the future.

Co-authorship network of co-authors of Ravi Vij

This figure shows the co-authorship network connecting the top 25 collaborators of Ravi Vij. A scholar is included among the top collaborators of Ravi Vij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravi Vij. Ravi Vij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trials 2025 ·Annals of Hematology ·Meletios Α. Dimopoulos, Kazutaka Sunami, Xavier Leleu, Ravi Vij, Cristina Gasparetto, Kenshi Suzuki, Sandrine Macé, (unknown), (unknown), Shinsuke Iida	1
2	Mixed-Methods Study on the Responsiveness of the Comprehensive Score for Financial Toxicity Among People With Multiple Myeloma 2024 ·JCO Oncology Practice ·Mark A. Fiala, (unknown), (unknown), (unknown), (unknown), Theresa Coles, Ravi Vij	5
3	Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma 2023 ·Blood ·(unknown), Zachary Crees, Michael Slade, Mark A. Schroeder, Ravi Vij, Geoffrey L. Uy, Keith Stockerl‐Goldstein	1
4	Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation 2023 ·Transplantation and Cellular Therapy ·(unknown), Jaebok Choi, Matthew Cooper, (unknown), Mark A. Fiala, Jingxia Liu, Iskra Pusic, Rizwan Romee, Amanda F. Cashen, Meagan A. Jacoby, Keith Stockerl‐Goldstein, Camille N. Abboud, Ravi Vij, Geoffrey L. Uy, Peter Westervelt, Matthew J. Walter, John F. DiPersio, Mark A. Schroeder	2
5	A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma 2022 ·Journal of Clinical Oncology ·Anita D’Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Katja Weisel, Orlando F. Bueno, (unknown), Kevin J. Freise, (unknown), Jeremy A. Ross, Akshanth R. Polepally, (unknown), Shane Lee, Ziyi Jin, Ben Buelow, Ravi Vij, Shaji Kumar	84
6	VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival 2020 ·Clinical Cancer Research ·Francesca Fontana, Michael J. Scott, John S. Allen, Xiaoxia Yang, Grace Cui, Dipanjan Pan, (unknown), Mark A. Fiala, Julie O’Neal, (unknown), Julie Ritchey, Michael P. Rettig, (unknown), Steven Fletcher, Ravi Vij, John F. DiPersio, Gregory M. Lanza	19
7	First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma 2020 ·Clinical Cancer Research ·Ravi Vij, Rajneesh Nath, Daniel Afar, María‐Victoria Mateos, Jesús G. Berdeja, Marc S. Raab, Andreas Guenther, Joaquín Martínez‐López, Andrzej Jakubowiak, Xavier Leleu, Katja Weisel, Shekman Wong, (unknown), James P. Sheridan, Anita Reddy, Bruno Paiva, Anil Singhal, Jesús F. San Miguel, Philippe Moreau	24
8	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma 2020 ·Cancers ·Jennifer Sun, Barbara Muz, Kinan Alhallak, (unknown), (unknown), Zhe Wang, (unknown), (unknown), Mark A. Fiala, Justin King, Daniel Kohnen, Noha N. Salama, Ravi Vij, Abdel Kareem Azab	66
9	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia 2019 ·Clinical Cancer Research ·Irene M. Ghobrial, Ravi Vij, David S. Siegel, Ashraf Badros, Jonathan L. Kaufman, Noopur Raje, Andrzej Jakubowiak, Michael R. Savona, Mihaela Obreja, Jesús G. Berdeja	39
10	Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013 2019 ·British Journal of Haematology ·Vincent Ribrag, David Avigan, Damian J. Green, Trisha M. Wise‐Draper, Juan G. Posada, Ravi Vij, Ying Zhu, Mohammed Z.H. Farooqui, Patricia Marinello, David S. Siegel	63
11	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen 2017 ·Cancer Medicine ·Alaa M. Ali, (unknown), Feng Gao, Geoffrey L. Uy, Amanda F. Cashen, Meagan A. Jacoby, Lukas D. Wartman, Armin Ghobadi, Iskra Pusic, Rizwan Romee, Todd A. Fehniger, Keith Stockerl‐Goldstein, Ravi Vij, Stephen T. Oh, Camille N. Abboud, Mark A. Schroeder, Peter Westervelt, John F. DiPersio, John S. Welch	21
12	Healthcare Resource Utilization and Costs Associated with Different Treatment Modalities of Relapsed/Refractory Multiple Myeloma Patients in the US: Findings from Preamble 2017 ·Blood ·David J. Kuter, Clara Chen, (unknown), Catherine Davis, Ravi Vij	1
13	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation 2017 ·Biology of Blood and Marrow Transplantation ·Yi-Shan Lee, Jingxia Liu, (unknown), (unknown), (unknown), (unknown), (unknown), Ravi Vij, Amanda F. Cashen, Camille N. Abboud, Peter Westervelt, Nancy L. Bartlett, John F. DiPersio, Friederike Kreisel, Kian‐Huat Lim	7
14	Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy 2017 ·Blood ·Mark A. Schroeder, Mark A. Fiala, Armin Ghobadi, Keith Stockerl‐Goldstein, Tanya M. Wildes, Ravi Vij	2
15	Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML 2016 ·Bone Marrow Transplantation ·Armin Rashidi, Michael Slade, John F. DiPersio, Peter Westervelt, Ravi Vij, Rizwan Romee	25
16	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia 2012 ·Blood ·Geoffrey L. Uy, Michael P. Rettig, Ibraheem Motabi, Kyle McFarland, Kathryn Trinkaus, Lindsay Hladnik, Shashikant Kulkarni, Camille N. Abboud, Amanda F. Cashen, Keith Stockerl‐Goldstein, Ravi Vij, Peter Westervelt, John F. DiPersio	310
17	A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma 2012 ·Blood ·Andrzej Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Ammar Al-Zoubi, Tara Anderson, (unknown), Kristen Detweiler‐Short, Keith Stockerl‐Goldstein, Asra Ahmed, (unknown), Diane E. Durecki, Kathryn McDonnell, M. Mietzel, Daniel R. Couriel, Mark Kaminski, Ravi Vij	311
18	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia 2010 ·Blood ·Todd A. Fehniger, Geoffrey L. Uy, Kathryn Trinkaus, (unknown), (unknown), Camille N. Abboud, Amanda F. Cashen, Keith Stockerl‐Goldstein, Peter Westervelt, John F. DiPersio, Ravi Vij	82
19	Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study 2008 ·Blood ·Drew J. Winston, Jo‐Anne H. Young, Vinod Pullarkat, Genovefa A. Papanicolaou, Ravi Vij, Estil Vance, George Alangaden, Roy F. Chemaly, Finn Bo Petersen, Nelson J. Chao, Jared Klein, Kellie Sprague, Stephen Villano, Michael Boeckh	177
20	Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction 2008 ·Blood ·Steven M. Devine, Ravi Vij, Michael P. Rettig, Laura Todt, (unknown), Nicholas M. Fisher, Hollie Devine, Daniel C. Link, Gary Calandra, Gary Bridger, Peter Westervelt, John F. DiPersio	234

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact